Gabe Loewinger
@gabeloewinger.bsky.social
Machine learning research scientist @ NIMH interested in statistics, optimization, ML, neuroscience, Brazilian jiu-jitsu, cats.
The FDA's MDMA decision exposed a major challenge in psychedelic research: participants know when they got the real drug (hard to miss the "trip"). So how do we interpret results from psychedelic RCTs?
Do benefits come from the compound itself or heightened expectancies about symptom improvement?
Do benefits come from the compound itself or heightened expectancies about symptom improvement?
December 9, 2025 at 5:41 PM
The FDA's MDMA decision exposed a major challenge in psychedelic research: participants know when they got the real drug (hard to miss the "trip"). So how do we interpret results from psychedelic RCTs?
Do benefits come from the compound itself or heightened expectancies about symptom improvement?
Do benefits come from the compound itself or heightened expectancies about symptom improvement?
Test effects of behavior/events at every trial timepoint in photometry analyses! Paper with Erjia Cui, Dave Lovinger, Francisco Pereira. “A Statistical Framework for Analysis of Trial-Level Temporal Dynamics in Fiber Photometry Experiments.” Python+R packages! elifesciences.org/articles/95802. 1/13
March 18, 2025 at 10:05 PM
Test effects of behavior/events at every trial timepoint in photometry analyses! Paper with Erjia Cui, Dave Lovinger, Francisco Pereira. “A Statistical Framework for Analysis of Trial-Level Temporal Dynamics in Fiber Photometry Experiments.” Python+R packages! elifesciences.org/articles/95802. 1/13